Healthcare Industry News: Treximet
News Release - July 27, 2016
Pernix Therapeutics Announces Reorganization of Senior Management TeamJohn Sedor Appointed CEO on a Permanent Basis
Company Names Pharmaceutical Industry Veteran, Dr. Graham Miao, as President & CFO
Company Positioned to Maximize Value and Drive Revenue Growth and Profitability
MORRISTOWN, N.J., July 26, 2016 -- (Healthcare Sales & Marketing Network) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced a reorganization of the Company’s senior management team intended to improve Pernix’s efficiency, drive profitability and position the Company for future growth. As part of the management change, John Sedor will assume the role of Chief Executive Officer on a permanent basis and pharmaceutical industry veteran, Dr. Graham Miao, who has served as a senior advisor to Pernix’s Board of Directors since May, has been appointed as President and Chief Financial Officer. Dr. Miao will report directly to Mr. Sedor and will have responsibility for all functions related to finance, operations, regulatory and scientific affairs.
“These changes to our senior management team, which are another step forward following our recently announced restructuring of Pernix’s sales force, flatten our organization, reduce our cost structure and improve our efficiency. We believe this management reorganization optimally positions Pernix for future revenue growth and profitability, and supports our goal of maximizing shareholder value,” said Mr. Sedor. “Based on my thorough review of our organization since joining the Company in May, it has become clear to me that Pernix has significant growth opportunities. The recent strong prescription trends for Zohydro ER, Treximet and Silenor support this belief. Going forward, our focus will be on enhancing revenue growth of the current brands, especially Zohydro ER, which we view as a major value driver for Pernix, as well as pursuing other growth opportunities.”
“I am pleased to be joining the dedicated and talented Pernix team at such a critical point in the Company’s history,” said Dr. Miao. “I firmly believe that Pernix is well-positioned for long-term success. We are in the process of working to improve execution of our strategy with financial discipline as well as evaluate opportunities to optimize the current capital structure and maximize shareholder value.”
In addition, Sanjay Patel, Chief Financial Officer, Terence Novak, Chief Operating Officer, and Barry Siegel, Senior Vice President and General Counsel are no longer employed by Pernix. These departures do not reflect any disagreements about the Company's financial results or disclosures.
Pernix intends to regain compliance with NASDAQ listing qualifications within the required time frame.
Mr. Sedor has served as interim CEO and Chairman of the Board of Pernix since May 2016. Mr. Sedor is also Chairman and CEO of Sedor Pharmaceuticals. Prior to this, Mr. Sedor served as President, CEO and Director of Cangene Corporation, one of the world’s leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
Prior to serving as a senior advisor to Pernix’s Board of Directors, Dr. Miao was EVP and CFO of Interpace Diagnostics Group, Inc. (formerly known as PDI, Inc.), a publicly traded healthcare commercialization company from October 2014 to March 2016. In this role, he directed all aspects of finance, investor relations, strategic business planning, M&A, and legal affairs. He helped achieve double-digit revenue growth and lead the successful sale of PDI’s contract sales business to Publicis Healthcare. From 2011 to 2014, Dr. Miao was the EVP and CFO, and later added additional roles as interim Co-President & Co-CEO, of Delcath Systems, Inc., a publicly traded specialty pharmaceutical and medical device company, responsible for all finance-related functions and operations, corporate and business development, mergers and acquisitions, and the legal and human resource departments. Prior to Delcath, Dr. Miao served as Chief of Staff for the Global CFO organization at Dun & Bradstreet Corporation and EVP and CFO at Pagoda Pharmaceuticals. He has also held various positions of increasing responsibility at leading global pharmaceutical and finance companies, including Schering-Plough Corporation, Pharmacia Corporation, J.P. Morgan and Roche. Dr. Miao holds a Ph.D. and MBA from Columbia University.
Source: Pernix Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.